Luciana Werneck Zuccherato and Colleagues on A3 domain of FVIII in Severe Hemophilia A
RPTH Journal shared on LinkedIn:
”This new study sequenced 265 individuals with severe hemophilia A from an admixed population and found 97 unique F8 mutations, 33% were novel.
Intron 22 inversions increased inhibitor risk nearly 5-fold, while missense variants were protective.
Mutations clustered differently by inhibitor status (A3 vs A1 domains), underscoring how F8 genotype shapes immune response.
These insights may guide development of less immunogenic FVIII therapies.”
Read the full article in RPTH.
Article: Deleterious variants cluster in the A3 domain of factor VIII in people with severe hemophilia A and inhibitors
Authors: Luciana Werneck Zuccherato, Renan Pedra Souza, Ricardo Mesquita Camelo, Márcio Antônio Portugal Santana, Maíse Moreira Dias, Letícia Lemos Jardim, Andrea Gonçalves de Oliveira, Claudia Santos Lorenzato, Monica Hermida Cerqueira, Vivian Karla Brognoli Franco, Rosangela de Albuquerque Ribeiro, Leina Yukari Etto, Maria do Rosario Ferraz Roberti, Fábia Michelle Rodrigues de Araújo Callado, Maria Aline Ferreira de Cerqueira, Ieda Solange de Souza Pinto, Andrea Aparecida Garcia, Tania Hissa Anegawa, Daniele Campos Fontes Neves, Daniel Gonçalves Chaves, Suely Meireles Rezende, on behalf of the HEMFIL and the Brazilian Immune Tolerance (BrazIT) Study
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 18, 2025, 16:59Raul Santos Gave 2 Talks at SAC 2025: On The Role of LDL-C and Future of Lipid-lowering Therapies
-
Oct 18, 2025, 16:57Marilena Vrana: What An Inspiring Week at The 2025 Plasma Protein Forum and Business Forum
-
Oct 18, 2025, 16:53Caitlin Raymond: When Technology Meets Physiology in Neonatal Patients
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 18, 2025, 16:56Alexandra Whiteside on Improving Coagulation Kinetics
-
Oct 18, 2025, 16:52Wolfgang Miesbach on Differential Diagnosis of Thrombocytopenia
-
Oct 18, 2025, 16:49Arisa Chuklin, Thita Joy Chiasakul, and Noppacharn Uaprasert on Management of Thrombosis in Behçet’s Syndrome
-
Oct 18, 2025, 16:47State of the Art Review On Angina After PCI From Javier Escaned's Team
-
Oct 18, 2025, 16:25Luciana Werneck Zuccherato and Colleagues on A3 domain of FVIII in Severe Hemophilia A
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 18, 2025, 16:55Emilia Arturo: Your Reminder to Donate Blood If You Can, When You Can
-
Oct 18, 2025, 16:51Allison Wheeler Rallies Support for Magdalena Lewandowska's NYC Marathon Run Benefiting NBDF
-
Oct 17, 2025, 16:07WFH Volunteer Mary Byrne Transforms Bleeding Disorder Diagnostics
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success